breast cancer and glp 1 Is GLP-1 Safe for Survivors? Evidence Guidance – Bolt Pharmacy SABCS 2025: Can GLP-1s Help

MASLD assessment in DIO-MASH mice The therapeutic potential of amycretin in improving liver health was evaluated in GAN DIO-MASH mice over a 12-week period

In this study, researchers analyzed data from more than 450,000 adults with type 2 diabetes who started either a GLP-1 drug or a dipeptidyl peptidase-4 inhibitor (known as DPP-4 inhibitor)

A systematic review and meta-analysis published in eClinicalMedicine found that discontinuing GLP-1 receptor agonist treatment led to an average weight regain of 5.63 kg and 5.81% of body weight across all patients studied

And sequence determines outcome

Many of our patients come to us with real questions, real concerns, and a desire for straight answers

[DOI] [PubMed] [Google Scholar] 145.Balestrieri M.L., Rizzo M.R., Barbieri M., Paolisso P., DOnofrio N., Giovane A., Siniscalchi M., Minicucci F., Sardu C., DAndrea D., et al